Trials / Withdrawn
WithdrawnNCT01272414
Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Currently there are few therapeutic options for the treatment of lid retraction secondary to thyroid orbitopathy (TO) during the active stages of the disease. BoTox injection is capable of creating a ptosis, that in the setting of TO can return the upper lid to a more physiologic position, thus improving cosmesis, corneal lubrication and potentially quiescent stage lid position. This investigation aims to examine the properties of this relationship.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum Toxin Type A | 2-12 units in weekly 2u doses to effect |
| DRUG | Saline injection | Injection of 0.4cc 0.9% normal saline |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-01-01
- Completion
- 2012-02-01
- First posted
- 2011-01-07
- Last updated
- 2015-06-03
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01272414. Inclusion in this directory is not an endorsement.